Program
Neuroaid
Also written as “MLC901”, “MLC 901” and “NeuroAiD”.
Its studies are mostly in Ischemic Stroke · Alzheimer Disease · Spinal Cord Injuries · Brain Injuries, Traumatic · Cerebral Infarction, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Moleac Pte | 41 open or running | phase 4since Aug 27, 2015 | Jul 22, 2008 | Feb 2029phase 3 · NCT07191028 |
| EVD Pharmacy and Medical | 11 open or running | phase 4since Sep 14, 2026 | Sep 14, 2026 | Sep 2027phase 4 · NCT07828210 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 22, 2008First study: phase 2 study in StrokeNew to Moleac PteMoleac Pte · NCT00721825 · 40 enrolled · Singapore
- Aug 27, 2015Phase 4 study in Spinal Cord InjuriesMoleac Pte · NCT02537899 · 30 enrolled · Malaysia
- Apr 19, 2021Phase 3 study in Brain Injuries, TraumaticMoleac Pte · NCT04861688 · 182 enrolled · Russian Federation
- Sep 2, 2025Phase 3 study in Alzheimer DiseaseMoleac Pte · NCT07191028 · 350 planned · Singapore
- Sep 14, 2026EVD Pharmacy and Medical's first study: phase 4 study in StrokeNew to EVD Pharmacy and MedicalEVD Pharmacy and Medical · NCT07828210 · 80 planned · Vietnam
Ahead
- Sep 2027Primary completion: phase 4 study in StrokeEVD Pharmacy and Medical · NCT07828210
- Feb 2029Primary completion: phase 3 study in Alzheimer DiseaseMoleac Pte · NCT07191028
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07828210Stroke · Vietnam | 4 | Recruiting | EVD Pharmacy and Medical | Sep 2027 | 80 |
| NCT07191028Alzheimer Disease · Singapore | 3 | Not yet recruiting | Moleac Pte | Feb 2029 | 350 |
| NCT04861688Brain Injuries, Traumatic · Russian Federation | 3 | Completed | Moleac Pte | Feb 14, 2023 | 182 |
| NCT02537899Spinal Cord Injuries · Malaysia | 4 | Completed | Moleac Pte | Sep 20, 2023 | 30 |
| NCT00721825Stroke · Singapore | 2 | Completed | Moleac Pte | Jul 2008 | 40 |
How it is read
Names in the registry
- “MLC901”, 1 entry
- “MLC 901”, 1 entry
- “NeuroAiD”, 1 entry
- “Traditional Chinese Medicine (NeuroAiD II™ (MLC901)”, 1 entry
- “Neuroaid”, 1 entry
Conditions, from the studies’ own filings
- Ischemic Stroke, 1 study
- Alzheimer Disease, 1 study
- Spinal Cord Injuries, 1 study
- Brain Injuries, Traumatic, 1 study
- Cerebral Infarction, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.